With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require ...
Abstract PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration ...
For patients with breast cancer, administration of pegfilgrastim 72 hours postchemotherapy reduces pegfilgrastim-induced bone pain (PIBP) compared with administration at 24 and 48 hours, according to ...
Neulasta (pegfilgrastim) is prescribed to help prevent serious infection from chemotherapy for certain cancers, and from a certain form of radiation sickness. It’s a biologic drug that comes as an ...
BLOOMFIELD, Conn., June 13, 2023 /PRNewswire/ -- A new study by Cigna Healthcare found that site-of-care redirection is associated with favorable clinical outcomes and increased access and ...
Lower rates of severe bone pain incidence seen for the 72-hour group vs 24- and 48-hour groups. HealthDay News — For patients with breast cancer, administration of pegfilgrastim 72 hours ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results